# CytoMed Therapeutics Limited (GDTC)

Source: https://www.quantisnow.com/company/GDTC
Generated: 2026-11-09T12:57:56.414Z

- Ticker: GDTC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2023
- SEC CIK: 0001873093

## Latest GDTC news and filings

- 2026-10-09 23:43 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6743850)
- 2026-10-09 20:30 UTC [CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency](https://www.quantisnow.com/insight/cytomed-therapeutics-limited-announces-receipt-of-nasdaq-notification-regarding-minimum-6742996)
- 2026-09-30 13:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6730260)
- 2026-07-25 01:01 UTC [Insider Buy] [Amendment: Director Choo Chee Kong bought $300,000 worth of ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED (200,000 units at $1.50), increasing direct ownership by 46% to 630,324 units (SEC Form 4)](https://www.quantisnow.com/insight/amendment-director-choo-chee-kong-bought-300000-worth-of-ordinary-6648742)
- 2026-07-24 16:33 UTC [Insider Buy] [SEC Form 4 filed by Director Choo Chee Kong](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-choo-chee-kong-6648132)
- 2026-06-23 16:14 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6612235)
- 2026-06-15 10:15 UTC [Insider Buy] [Director Choo Chee Kong bought $128,778 worth of Ordinary Shares (112,000 units at $1.15), increasing direct ownership by 35% to 430,324 units (SEC Form 4)](https://www.quantisnow.com/insight/director-choo-chee-kong-bought-128778-worth-of-ordinary-shares-6601686)
- 2026-06-03 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6586684)
- 2026-05-26 13:00 UTC [SEC Form 3] [New insider Toh Keng Kiat claimed ownership of 4,000 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-toh-keng-kiat-claimed-ownership-of-4000-units-6571566)
- 2026-05-15 13:00 UTC [SEC Form 3] [New insider Choo Chee Kong claimed ownership of 2,587,746 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-choo-chee-kong-claimed-ownership-of-2587746-units-6556091)
- 2026-05-15 13:00 UTC [SEC Form 3] [New insider Yew Chak Hua claimed ownership of 2,469 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-yew-chak-hua-claimed-ownership-of-2469-units-6556090)
- 2026-05-15 13:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Leong Mark Kei Wei](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-leong-mark-kei-6556089)
- 2026-05-15 13:00 UTC [SEC Form 3] [New insider Goh Yvonne claimed ownership of 25,781 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-goh-yvonne-claimed-ownership-of-25781-units-of-6556085)
- 2026-05-15 13:00 UTC [SEC Form 3] [New insider Tan Yoong Ying claimed ownership of 25,781 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-tan-yoong-ying-claimed-ownership-of-25781-units-6556083)
- 2026-05-15 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6555777)
- 2026-05-11 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6543805)
- 2026-04-14 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6499600)
- 2026-03-31 13:36 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6478425)
- 2026-03-31 12:01 UTC [SEC Form 20-F filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-cytomed-therapeutics-limited-6478039)
- 2026-01-28 16:41 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6363677)
- 2026-01-28 15:00 UTC [CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress](https://www.quantisnow.com/insight/cytomed-therapeutics-refutes-misleading-claims-and-reaffirms-clinical-progress-6363600)
- 2026-01-13 13:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6347430)
- 2026-01-13 13:00 UTC [CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital](https://www.quantisnow.com/insight/cytomed-therapeutics-new-year-update-and-seeks-shareholders-feedback-on-6347392)
- 2025-12-08 13:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6306252)
- 2025-12-08 13:00 UTC [CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia](https://www.quantisnow.com/insight/cytomed-therapeutics-announces-novel-first-in-human-clinical-trial-collaborations-with-renowned-6306204)
- 2025-11-18 13:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6284057)
- 2025-11-18 13:00 UTC [CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India](https://www.quantisnow.com/insight/cytomed-therapeutics-completes-acquisition-of-t-cell-technology-from-uk-6283982)
- 2025-11-06 13:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6264279)
- 2025-11-06 13:00 UTC [CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy](https://www.quantisnow.com/insight/cytomed-therapeutics-secures-non-dilutive-investment-for-subsidiary-longevitybank-from-ich-6264260)
- 2025-10-22 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6241000)
- 2025-10-22 12:00 UTC [CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95%](https://www.quantisnow.com/insight/cytomed-therapeutics-chairman-increases-effective-holdings-to-2195-6240964)
- 2025-10-15 12:45 UTC [Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge](https://www.quantisnow.com/insight/cellular-immunotherapy-breakthroughs-fuel-370-billion-market-surge-6233497)
- 2025-10-14 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6231486)
- 2025-10-14 12:00 UTC [CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets](https://www.quantisnow.com/insight/cytomed-makes-cash-bid-for-potential-acquisition-of-tc-biopharm-6231417)
- 2025-10-02 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6219100)
- 2025-10-02 11:00 UTC [CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia](https://www.quantisnow.com/insight/cytomed-therapeutics-announces-publication-of-collaborative-research-with-the-university-6219077)
- 2025-09-30 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6215226)
- 2025-08-28 13:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6181954)
- 2025-08-28 13:00 UTC [Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition](https://www.quantisnow.com/insight/update-on-recent-acquisition---cytomed-therapeutics-expands-into-auto-immune-6181907)
- 2025-08-19 01:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by CytoMed Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-cytomed-therapeutics-limited-6170794)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GDTC
- Earnings history: https://www.quantisnow.com/earnings/GDTC
- Dividend history: https://www.quantisnow.com/dividends/GDTC
- Insider transactions: https://www.quantisnow.com/insiders/GDTC
- Options chain: https://www.quantisnow.com/options/GDTC
- SEC 8-K filings only: https://www.quantisnow.com/company/GDTC/8-k
- RSS and alerts for GDTC: https://www.quantisnow.com/docs/rss-feeds.md